Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Mylan CEO Heather Bresch continues to defend the high cost of EpiPens by pointing out that middlemen in the drug's supply chain take 55 percent of the medication's list price, according to Health Affairs.
An Atlanta AIDS group filed a federal complaint against Humana and Cigna, arguing that the insurance companies' high prices for HIV medications discriminate against those with the disease, according to The Atlanta Journal-Constitution.
Since 2007, the price of EpiPens has increased by more than 400 percent, forcing some patients to pay as much as $700 for the medication. Mylan, the Canonsburg, Pa.-based company behind the life-saving medication, is facing large scrutiny from the media,…
"It's a struggle for all hospitals. It's something we talk about nearly every day."
New York attorney general investigates Mylan over potential antitrust violations in school contracts
New York Attorney General Eric Schneiderman launched an investigation Tuesday into EpiPen maker Mylan over antitrust concerns in its contracts with school systems, reported CNBC.
Tonix Pharmaceuticals' experimental drug failed to treat fibromyalgia in a recent clinical study, causing the New York–based company to focus on developing the drug as a treatment for post-traumatic stress disorder, reported Reuters.
Imprimis Pharmaceuticals developed the Imprimis Cares Access Network, a patient assistance program intended to improve access to the San Diego drugmaker's compounded medications and lower patients' out-of-pocket costs.
Logistic and transportation companies created 14,900 new jobs in August, despite a recent lull in shipping volumes and manufacturing activity in 2016, according to a report released by the U.S. Labor Department Friday.
Danaher will purchase Cepheid, a medical diagnostics company located in Sunnyvale, Calif., for a value of $4 billion, according to Reuters.
The Food and Drug Administration granted orphan drug status to Firdapse, an experimental treatment for patients with myasthenia gravis, a degenerative neuromuscular disease similar to Parkinson's or Lou Gehrig's disease, according to South Florida Business Journal.